Katano Satoshi, Yamano Kotaro, Yano Toshiyuki, Numazawa Ryo, Nagaoka Ryohei, Honma Suguru, Fujisawa Yusuke, Miki Yasuhiro, Takamura Yuhei, Kunihara Hayato, Fujisaki Hiroya, Kouzu Hidemichi, Ohori Katsuhiko, Katayose Masaki, Hashimoto Akiyoshi, Furuhashi Masato
Division of Rehabilitation, Sapporo Medical University Hospital, Sapporo, Japan; Second Division of Physical Therapy, Sapporo Medical University School of Health Science, Sapporo, Japan.
Division of Rehabilitation, Sapporo Medical University Hospital, Sapporo, Japan; Second Division of Physical Therapy, Sapporo Medical University School of Health Science, Sapporo, Japan.
J Nutr Health Aging. 2025 Jan;29(1):100434. doi: 10.1016/j.jnha.2024.100434. Epub 2024 Dec 5.
The utility of the updated Asian Working Group for Sarcopenia (AWGS) criteria in diagnosing sarcopenia in older patients with heart failure (HF) remains unclear.
To analyze the prevalence and prognostic impact of sarcopenia diagnosed by the updated AWGS criteria in older patients with HF.
Ambispective cohort study.
SETTING & SUBJECTS: 534 older patients with HF from a university hospital in Japan.
Sarcopenia was assessed using different versions of the AWGS criteria: AWGS 2014, AWGS 2019H (muscle mass relative to height squared), and AWGS 2019B (muscle mass relative to BMI). The primary endpoint was all-cause mortality at three years post-discharge.
Of 534 patients, 42%, 57%, and 44% were diagnosed with sarcopenia according to AWGS 2014, AWGS 2019H, AWGS 2019B, respectively. Among patients without AWGS 2014-defined sarcopenia, 23% were reclassified as having sarcopenia by AWGS 2019H criteria. Forty-four percent of sarcopenic patients diagnosed by AWGS 2019H were re-classified as non-sarcopenic by AWGS 2019B, with lower fat mass and poorer nutritional status. After the multivariate Cox proportional hazard analyses, an association between all-cause death and sarcopenia remained significant for AWGS 2014 (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.01-2.37) and AWGS 2019H (HR, 1.65; 95% CI, 1.05-2.59), but not for AWGS 2019B (HR, 0.99; 95% CI, 0.64-1.51).
The updated AWGS 2019H criteria detected more sarcopenic patients with HF while maintaining favorable predictive ability. The use of BMI-adjusted muscle mass reclassified underweight and malnourished patients as non-sarcopenic, limiting its impact on the mortality prediction in older patients with HF.
更新后的亚洲肌少症工作组(AWGS)标准在诊断老年心力衰竭(HF)患者肌少症方面的效用仍不明确。
分析采用更新后的AWGS标准诊断的老年HF患者肌少症的患病率及其对预后的影响。
双向队列研究。
来自日本一家大学医院的534例老年HF患者。
采用不同版本的AWGS标准评估肌少症:AWGS 2014、AWGS 2019H(肌肉量相对于身高平方)和AWGS 2019B(肌肉量相对于体重指数)。主要终点为出院后三年的全因死亡率。
在534例患者中,根据AWGS 2014、AWGS 2019H、AWGS 2019B标准诊断为肌少症的患者分别占42%、57%和44%。在无AWGS 2014定义的肌少症患者中,23%根据AWGS 2019H标准重新分类为有肌少症。AWGS 2019H诊断为肌少症的患者中,44%根据AWGS 2019B重新分类为非肌少症,这些患者脂肪量较低且营养状况较差。经过多变量Cox比例风险分析,AWGS 2014(风险比[HR],1.55;95%置信区间[CI],1.01 - 2.37)和AWGS 2019H(HR,1.65;95% CI,1.05 - 2.59)诊断的肌少症与全因死亡之间的关联仍具有统计学意义,但AWGS 2019B(HR,0.99;95% CI,0.64 - 1.51)无此关联。
更新后的AWGS 2019H标准检测出更多HF肌少症患者,同时保持了良好的预测能力。使用体重指数调整后的肌肉量将体重过轻和营养不良患者重新分类为非肌少症,限制了其对老年HF患者死亡率预测的影响。